Harry Rogoff, PhD, joined the Belfer Office for Dana-Farber Innovations as Business Director, Therapeutics in 2022. Dr. Rogoff has been leading oncology drug discovery in industry for close to 20 years at ArQule, as a founding member of Boston Biomedical, and at Sumitomo Pharma Oncology (SMP Oncology), where he contributed to multiple compounds that entered clinical development. Prior to joining BODFI, Dr. Rogoff performed alliance management and scientific diligence as part of the external innovation group at SDP Oncology and worked directly with academic investigators at The Wistar Institute to help advance their early discovery stage assets. Dr. Rogoff received his PhD in Biology from the University of Massachusetts Medical School, Graduate School of Biological Sciences in 2004, and his Bachelor of Arts from Bates College.
